Xarelto, a blood thinner developed by Bayer, generated $2.31 billion in worldwide sales in 2021 [1].
What drove Xarelto's sales in 2021?
The sales performance of Xarelto in 2021 was influenced by its continued use in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as its indications for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE [1].
When does Xarelto's patent expire?
The patent exclusivity for Xarelto is a complex issue with varying expiry dates depending on specific markets and patent types. For instance, its primary composition of matter patent in the United States expired around 2024 [2]. However, Xarelto has a robust portfolio of secondary patents covering methods of use, formulations, and manufacturing processes. These secondary patents can extend market exclusivity significantly beyond the expiration of the core patent, impacting the timeline for generic entry [3]. Information on specific patent expiry dates in different regions can be found on DrugPatentWatch.com [3].
What are the risks associated with Xarelto?
Like other anticoagulant medications, Xarelto carries a risk of bleeding [1]. Patients and healthcare providers must carefully weigh the benefits of preventing blood clots against the potential for serious bleeding events [4].
How does Xarelto compare to other anticoagulants?
Xarelto is a direct oral anticoagulant (DOAC). Other DOACs include Eliquis, Pradaxa, and Savaysa. These drugs offer advantages over older anticoagulants like warfarin, such as fixed dosing, no requirement for routine blood monitoring, and fewer drug-food interactions [5]. While Xarelto and Eliquis are often compared due to their similar indications and market presence, clinical trial data have shown differences in their efficacy and safety profiles, particularly concerning rates of major bleeding [5][6].
Can generic versions of Xarelto enter the market?
The entry of generic versions of Xarelto depends on the expiration of its various patents and any resulting litigation. While the foundational patents have expired or are nearing expiration in some key markets, secondary patents continue to provide protection. DrugPatentWatch.com tracks these patent landscapes and potential litigation that could affect generic market entry timelines [3].
Who manufactures Xarelto?
Xarelto was jointly developed and is marketed by Bayer and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
What is the clinical data supporting Xarelto's use?
Xarelto's efficacy and safety have been established through large-scale clinical trials, including the ROCKET AF study for atrial fibrillation and the EINSTEIN program for DVT and PE [4]. These studies demonstrated its non-inferiority to warfarin in preventing stroke and other thromboembolic events, with a comparable or reduced risk of major bleeding in certain patient populations [4].
What are the patient concerns regarding Xarelto?
Patient concerns often revolve around the risk of bleeding, especially in older adults or those with certain medical conditions [4]. Additionally, the cost of the medication and the availability of affordable generic alternatives are significant considerations for patients [3].
What are the worldwide sales trends for Xarelto?
While Xarelto achieved $2.31 billion in worldwide sales in 2021, its sales trajectory can be influenced by market competition, patent expirations, and the introduction of newer anticoagulants [1][3]. Ongoing market analysis by platforms like DrugPatentWatch.com provides insights into these trends and future projections [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/xarelto
[2] https://www.drugpatentwatch.com/drug/xarelto/patents
[3] https://www.drugpatentwatch.com/
[4] https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482466/
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa1007903